APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Leiomyosarcoma Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Leiomyosarcoma Drug Industry Growth and Trends Forecast to 2032

Report ID 174006840119 December 202592 pages

Choose your research edition.

Industry ResearchLeiomyosarcoma Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Leiomyosarcoma Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Leiomyosarcoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Leiomyosarcoma Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Leiomyosarcoma Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Leiomyosarcoma Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Leiomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Leiomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Leiomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Leiomyosarcoma Drug include Novartis AG, Merck & Co., Inc., Vicore Pharma AB, Mirati Therapeutics Inc., Karyopharm Therapeutics, Inc., Cell Medica Limited, BeiGene, Ltd. and Advenchen Laboratories, LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Leiomyosarcoma Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Leiomyosarcoma Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Leiomyosarcoma Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Leiomyosarcoma Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Leiomyosarcoma Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Leiomyosarcoma Drug Market by Company

Novartis AG

Merck & Co., Inc.

Vicore Pharma AB

Mirati Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Cell Medica Limited

BeiGene, Ltd.

Advenchen Laboratories, LLC

Leiomyosarcoma Drug Segment by Type

BGB-290

C-21

AL-3818

Others

Leiomyosarcoma Drug Segment by Application

Clinic

Hospital

Others

Leiomyosarcoma Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leiomyosarcoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Leiomyosarcoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leiomyosarcoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Leiomyosarcoma Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Leiomyosarcoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of BGB-290 Table 2. Major Company of C-21 Table 3. Major Company of AL-3818 Table 4. Major Company of Others Table 5. Global Leiomyosarcoma Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Leiomyosarcoma Drug Sales by Type (2021-2026) & (K Units) Table 7. Global Leiomyosarcoma Drug Sales Market Share in Volume by Type (2021-2026) Table 8. Global Leiomyosarcoma Drug Sales by Type (2021-2026) & (US$ Million) Table 9. Global Leiomyosarcoma Drug Sales Market Share in Value by Type (2021-2026) Table 10. Global Leiomyosarcoma Drug Price by Type (2021-2026) & (US$/Unit) Table 11. Global Leiomyosarcoma Drug Sales by Type (2027-2032) & (K Units) Table 12. Global Leiomyosarcoma Drug Sales Market Share in Volume by Type (2027-2032) Table 13. Global Leiomyosarcoma Drug Sales by Type (2027-2032) & (US$ Million) Table 14. Global Leiomyosarcoma Drug Sales Market Share in Value by Type (2027-2032) Table 15. Global Leiomyosarcoma Drug Price by Type (2027-2032) & (US$/Unit) Table 16. North America Leiomyosarcoma Drug Sales by Type (2021-2026) & (K Units) Table 17. North America Leiomyosarcoma Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Leiomyosarcoma Drug Sales by Type (2021-2026) & (K Units) Table 19. Europe Leiomyosarcoma Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Leiomyosarcoma Drug Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Leiomyosarcoma Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Leiomyosarcoma Drug Sales by Type (2021-2026) & (K Units) Table 23. Latin America Leiomyosarcoma Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Leiomyosarcoma Drug Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Leiomyosarcoma Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Leiomyosarcoma Drug Industry Trends Table 27. Leiomyosarcoma Drug Industry Drivers Table 28. Leiomyosarcoma Drug Industry Opportunities and Challenges Table 29. Leiomyosarcoma Drug Industry Restraints Table 30. Global Leiomyosarcoma Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Leiomyosarcoma Drug Revenue Market Share by Company (2021-2026) Table 32. Global Leiomyosarcoma Drug Sales by Company (2021-2026) & (K Units) Table 33. Global Leiomyosarcoma Drug Sales Share by Company (2021-2026) Table 34. Global Leiomyosarcoma Drug Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Leiomyosarcoma Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Leiomyosarcoma Drug Major Company Production Sites and Headquarters Table 37. Global Leiomyosarcoma Drug Company, Product Type & Application Table 38. Global Leiomyosarcoma Drug Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Leiomyosarcoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Leiomyosarcoma Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Leiomyosarcoma Drug Sales by Region (2021-2026) & (K Units) Table 43. Global Leiomyosarcoma Drug Sales Market Share in Volume by Region (2021-2026) Table 44. Global Leiomyosarcoma Drug Sales by Region (2021-2026) & (US$ Million) Table 45. Global Leiomyosarcoma Drug Sales Market Share in Value by Region (2021-2026) Table 46. Global Leiomyosarcoma Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Leiomyosarcoma Drug Sales by Region (2027-2032) & (K Units) Table 48. Global Leiomyosarcoma Drug Sales Market Share in Volume by Region (2027-2032) Table 49. Global Leiomyosarcoma Drug Sales by Region (2027-2032) & (US$ Million) Table 50. Global Leiomyosarcoma Drug Sales Market Share in Value by Region (2027-2032) Table 51. Global Leiomyosarcoma Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Leiomyosarcoma Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Leiomyosarcoma Drug Sales by Application (2021-2026) & (K Units) Table 54. Global Leiomyosarcoma Drug Sales Market Share in Volume by Application (2021-2026) Table 55. Global Leiomyosarcoma Drug Sales by Application (2021-2026) & (US$ Million) Table 56. Global Leiomyosarcoma Drug Sales Market Share in Value by Application (2021-2026) Table 57. Global Leiomyosarcoma Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Leiomyosarcoma Drug Sales by Application (2027-2032) & (K Units) Table 59. Global Leiomyosarcoma Drug Sales Market Share in Volume by Application (2027-2032) Table 60. Global Leiomyosarcoma Drug Sales by Application (2027-2032) & (US$ Million) Table 61. Global Leiomyosarcoma Drug Sales Market Share in Value by Application (2027-2032) Table 62. Global Leiomyosarcoma Drug Price by Application (2027-2032) & (US$/Unit) Table 63. North America Leiomyosarcoma Drug Sales by Application (2021-2026) & (K Units) Table 64. North America Leiomyosarcoma Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Leiomyosarcoma Drug Sales by Application (2021-2026) & (K Units) Table 66. Europe Leiomyosarcoma Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Leiomyosarcoma Drug Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Leiomyosarcoma Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Leiomyosarcoma Drug Sales by Application (2021-2026) & (K Units) Table 70. Latin America Leiomyosarcoma Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Leiomyosarcoma Drug Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Leiomyosarcoma Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Novartis AG Company Information Table 74. Novartis AG Business Overview Table 75. Novartis AG Leiomyosarcoma Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Novartis AG Leiomyosarcoma Drug Product Portfolio Table 77. Novartis AG Recent Development Table 78. Merck & Co., Inc. Company Information Table 79. Merck & Co., Inc. Business Overview Table 80. Merck & Co., Inc. Leiomyosarcoma Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Merck & Co., Inc. Leiomyosarcoma Drug Product Portfolio Table 82. Merck & Co., Inc. Recent Development Table 83. Vicore Pharma AB Company Information Table 84. Vicore Pharma AB Business Overview Table 85. Vicore Pharma AB Leiomyosarcoma Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Vicore Pharma AB Leiomyosarcoma Drug Product Portfolio Table 87. Vicore Pharma AB Recent Development Table 88. Mirati Therapeutics Inc. Company Information Table 89. Mirati Therapeutics Inc. Business Overview Table 90. Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Mirati Therapeutics Inc. Leiomyosarcoma Drug Product Portfolio Table 92. Mirati Therapeutics Inc. Recent Development Table 93. Karyopharm Therapeutics, Inc. Company Information Table 94. Karyopharm Therapeutics, Inc. Business Overview Table 95. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product Portfolio Table 97. Karyopharm Therapeutics, Inc. Recent Development Table 98. Cell Medica Limited Company Information Table 99. Cell Medica Limited Business Overview Table 100. Cell Medica Limited Leiomyosarcoma Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Cell Medica Limited Leiomyosarcoma Drug Product Portfolio Table 102. Cell Medica Limited Recent Development Table 103. BeiGene, Ltd. Company Information Table 104. BeiGene, Ltd. Business Overview Table 105. BeiGene, Ltd. Leiomyosarcoma Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. BeiGene, Ltd. Leiomyosarcoma Drug Product Portfolio Table 107. BeiGene, Ltd. Recent Development Table 108. Advenchen Laboratories, LLC Company Information Table 109. Advenchen Laboratories, LLC Business Overview Table 110. Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Advenchen Laboratories, LLC Leiomyosarcoma Drug Product Portfolio Table 112. Advenchen Laboratories, LLC Recent Development Table 113. North America Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 114. North America Leiomyosarcoma Drug Sales by Country (2021-2026) & (K Units) Table 115. North America Leiomyosarcoma Drug Sales Market Share by Country (2021-2026) Table 116. North America Leiomyosarcoma Drug Sales Forecast by Country (2027-2032) & (K Units) Table 117. North America Leiomyosarcoma Drug Sales Market Share Forecast by Country (2027-2032) Table 118. North America Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. North America Leiomyosarcoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 120. North America Leiomyosarcoma Drug Market Share by Country (2021-2026) Table 121. North America Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. North America Leiomyosarcoma Drug Market Share Forecast by Country (2027-2032) Table 123. Europe Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 124. Europe Leiomyosarcoma Drug Sales by Country (2021-2026) & (K Units) Table 125. Europe Leiomyosarcoma Drug Sales Market Share by Country (2021-2026) Table 126. Europe Leiomyosarcoma Drug Sales Forecast by Country (2027-2032) & (K Units) Table 127. Europe Leiomyosarcoma Drug Sales Market Share Forecast by Country (2027-2032) Table 128. Europe Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Europe Leiomyosarcoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 130. Europe Leiomyosarcoma Drug Market Share by Country (2021-2026) Table 131. Europe Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Europe Leiomyosarcoma Drug Market Share Forecast by Country (2027-2032) Table 133. Asia-Pacific Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 134. Asia-Pacific Leiomyosarcoma Drug Sales by Country (2021-2026) & (K Units) Table 135. Asia-Pacific Leiomyosarcoma Drug Sales Market Share by Country (2021-2026) Table 136. Asia-Pacific Leiomyosarcoma Drug Sales Forecast by Country (2027-2032) & (K Units) Table 137. Asia-Pacific Leiomyosarcoma Drug Sales Market Share Forecast by Country (2027-2032) Table 138. Asia-Pacific Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Asia-Pacific Leiomyosarcoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 140. Asia-Pacific Leiomyosarcoma Drug Market Share by Country (2021-2026) Table 141. Asia-Pacific Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Asia-Pacific Leiomyosarcoma Drug Market Share Forecast by Country (2027-2032) Table 143. Latin America Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 144. Latin America Leiomyosarcoma Drug Sales by Country (2021-2026) & (K Units) Table 145. Latin America Leiomyosarcoma Drug Sales Market Share by Country (2021-2026) Table 146. Latin America Leiomyosarcoma Drug Sales Forecast by Country (2027-2032) & (K Units) Table 147. Latin America Leiomyosarcoma Drug Sales Market Share Forecast by Country (2027-2032) Table 148. Latin America Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Latin America Leiomyosarcoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 150. Latin America Leiomyosarcoma Drug Market Share by Country (2021-2026) Table 151. Latin America Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Latin America Leiomyosarcoma Drug Market Share Forecast by Country (2027-2032) Table 153. Middle East and Africa Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 154. Middle East and Africa Leiomyosarcoma Drug Sales by Country (2021-2026) & (K Units) Table 155. Middle East and Africa Leiomyosarcoma Drug Sales Market Share by Country (2021-2026) Table 156. Middle East and Africa Leiomyosarcoma Drug Sales Forecast by Country (2027-2032) & (K Units) Table 157. Middle East and Africa Leiomyosarcoma Drug Sales Market Share Forecast by Country (2027-2032) Table 158. Middle East and Africa Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East and Africa Leiomyosarcoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East and Africa Leiomyosarcoma Drug Market Share by Country (2021-2026) Table 161. Middle East and Africa Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East and Africa Leiomyosarcoma Drug Market Share Forecast by Country (2027-2032) Table 163. Key Raw Materials Table 164. Raw Materials Key Suppliers Table 165. Leiomyosarcoma Drug Distributors List Table 166. Leiomyosarcoma Drug Customers List Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Leiomyosarcoma Drug Image Figure 2. Global Leiomyosarcoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Leiomyosarcoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Leiomyosarcoma Drug Sales (2021-2032) & (K Units) Figure 5. BGB-290 Image Figure 6. Global BGB-290 Sales YoY Growth (2021-2032) & (K Units) Figure 7. C-21 Image Figure 8. Global C-21 Sales YoY Growth (2021-2032) & (K Units) Figure 9. AL-3818 Image Figure 10. Global AL-3818 Sales YoY Growth (2021-2032) & (K Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Leiomyosarcoma Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Leiomyosarcoma Drug Market Share by Type 2025 VS 2032 Figure 15. North America Leiomyosarcoma Drug Sales Market Share in Volume by Type in 2025 Figure 16. North America Leiomyosarcoma Drug Sales Market Share in Value by Type in 2025 Figure 17. Europe Leiomyosarcoma Drug Sales Market Share in Volume by Type in 2025 Figure 18. Europe Leiomyosarcoma Drug Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Leiomyosarcoma Drug Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Leiomyosarcoma Drug Sales Market Share in Value by Type in 2025 Figure 21. Latin America Leiomyosarcoma Drug Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Leiomyosarcoma Drug Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Leiomyosarcoma Drug Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Leiomyosarcoma Drug Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Leiomyosarcoma Drug Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Clinic Image Figure 28. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Leiomyosarcoma Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Leiomyosarcoma Drug Market Share by Application 2025 VS 2032 Figure 35. North America Leiomyosarcoma Drug Sales Market Share in Volume by Application in 2025 Figure 36. North America Leiomyosarcoma Drug Sales Market Share in Value by Application in 2025 Figure 37. Europe Leiomyosarcoma Drug Sales Market Share in Volume by Application in 2025 Figure 38. Europe Leiomyosarcoma Drug Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Leiomyosarcoma Drug Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Leiomyosarcoma Drug Sales Market Share in Value by Application in 2025 Figure 41. Latin America Leiomyosarcoma Drug Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Leiomyosarcoma Drug Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Leiomyosarcoma Drug Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Leiomyosarcoma Drug Sales Market Share in Value by Application in 2025 Figure 45. North America Leiomyosarcoma Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Leiomyosarcoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Leiomyosarcoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Leiomyosarcoma Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Leiomyosarcoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Leiomyosarcoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Leiomyosarcoma Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Leiomyosarcoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Leiomyosarcoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Leiomyosarcoma Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Leiomyosarcoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Leiomyosarcoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Leiomyosarcoma Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Leiomyosarcoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Leiomyosarcoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Leiomyosarcoma Drug Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Leiomyosarcoma Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • BGB-290
  • C-21
  • AL-3818
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Vicore Pharma AB
  • Mirati Therapeutics Inc.
  • Karyopharm Therapeutics, Inc.
  • Cell Medica Limited
  • BeiGene, Ltd.
  • Advenchen Laboratories, LLC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Leiomyosarcoma Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Leiomyosarcoma Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Leiomyosarcoma Drug Market by Type
  6. 1.3.1 BGB-290
  7. 1.3.2 C-21
  8. 1.3.3 AL-3818
  9. 1.3.4 Others
  10. 1.4 Global Leiomyosarcoma Drug Market Size by Type
  11. 1.4.1 Global Leiomyosarcoma Drug Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Leiomyosarcoma Drug Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Leiomyosarcoma Drug Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Leiomyosarcoma Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Leiomyosarcoma Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Leiomyosarcoma Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Leiomyosarcoma Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Leiomyosarcoma Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Leiomyosarcoma Drug Industry Trends
  2. 2.2 Leiomyosarcoma Drug Industry Drivers
  3. 2.3 Leiomyosarcoma Drug Industry Opportunities and Challenges
  4. 2.4 Leiomyosarcoma Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Leiomyosarcoma Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Leiomyosarcoma Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Leiomyosarcoma Drug Price (2021-2026)
  4. 3.4 Global Leiomyosarcoma Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Leiomyosarcoma Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Leiomyosarcoma Drug Company, Product Type & Application
  7. 3.7 Global Leiomyosarcoma Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Leiomyosarcoma Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Leiomyosarcoma Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Leiomyosarcoma Drug Tier 1, Tier 2, and Tier 3
4 Leiomyosarcoma Drug Regional Status and Outlook
  1. 4.1 Global Leiomyosarcoma Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Leiomyosarcoma Drug Historic Market Size by Region
  3. 4.2.1 Global Leiomyosarcoma Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Leiomyosarcoma Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Leiomyosarcoma Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Leiomyosarcoma Drug Forecasted Market Size by Region
  7. 4.3.1 Global Leiomyosarcoma Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Leiomyosarcoma Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Leiomyosarcoma Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Leiomyosarcoma Drug by Application
  1. 5.1 Leiomyosarcoma Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Leiomyosarcoma Drug Market Size by Application
  6. 5.2.1 Global Leiomyosarcoma Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Leiomyosarcoma Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Leiomyosarcoma Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Leiomyosarcoma Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Leiomyosarcoma Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Leiomyosarcoma Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Leiomyosarcoma Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Leiomyosarcoma Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis AG
  2. 6.1.1 Novartis AG Company Information
  3. 6.1.2 Novartis AG Business Overview
  4. 6.1.3 Novartis AG Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis AG Leiomyosarcoma Drug Product Portfolio
  6. 6.1.5 Novartis AG Recent Developments
  7. 6.2 Merck & Co., Inc.
  8. 6.2.1 Merck & Co., Inc. Company Information
  9. 6.2.2 Merck & Co., Inc. Business Overview
  10. 6.2.3 Merck & Co., Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck & Co., Inc. Leiomyosarcoma Drug Product Portfolio
  12. 6.2.5 Merck & Co., Inc. Recent Developments
  13. 6.3 Vicore Pharma AB
  14. 6.3.1 Vicore Pharma AB Company Information
  15. 6.3.2 Vicore Pharma AB Business Overview
  16. 6.3.3 Vicore Pharma AB Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Vicore Pharma AB Leiomyosarcoma Drug Product Portfolio
  18. 6.3.5 Vicore Pharma AB Recent Developments
  19. 6.4 Mirati Therapeutics Inc.
  20. 6.4.1 Mirati Therapeutics Inc. Company Information
  21. 6.4.2 Mirati Therapeutics Inc. Business Overview
  22. 6.4.3 Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Mirati Therapeutics Inc. Leiomyosarcoma Drug Product Portfolio
  24. 6.4.5 Mirati Therapeutics Inc. Recent Developments
  25. 6.5 Karyopharm Therapeutics, Inc.
  26. 6.5.1 Karyopharm Therapeutics, Inc. Company Information
  27. 6.5.2 Karyopharm Therapeutics, Inc. Business Overview
  28. 6.5.3 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product Portfolio
  30. 6.5.5 Karyopharm Therapeutics, Inc. Recent Developments
  31. 6.6 Cell Medica Limited
  32. 6.6.1 Cell Medica Limited Company Information
  33. 6.6.2 Cell Medica Limited Business Overview
  34. 6.6.3 Cell Medica Limited Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Cell Medica Limited Leiomyosarcoma Drug Product Portfolio
  36. 6.6.5 Cell Medica Limited Recent Developments
  37. 6.7 BeiGene, Ltd.
  38. 6.7.1 BeiGene, Ltd. Company Information
  39. 6.7.2 BeiGene, Ltd. Business Overview
  40. 6.7.3 BeiGene, Ltd. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 BeiGene, Ltd. Leiomyosarcoma Drug Product Portfolio
  42. 6.7.5 BeiGene, Ltd. Recent Developments
  43. 6.8 Advenchen Laboratories, LLC
  44. 6.8.1 Advenchen Laboratories, LLC Company Information
  45. 6.8.2 Advenchen Laboratories, LLC Business Overview
  46. 6.8.3 Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Advenchen Laboratories, LLC Leiomyosarcoma Drug Product Portfolio
  48. 6.8.5 Advenchen Laboratories, LLC Recent Developments
7 North America by Country
  1. 7.1 North America Leiomyosarcoma Drug Sales by Country
  2. 7.1.1 North America Leiomyosarcoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Leiomyosarcoma Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Leiomyosarcoma Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Leiomyosarcoma Drug Market Size by Country
  6. 7.2.1 North America Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Leiomyosarcoma Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Leiomyosarcoma Drug Sales by Country
  2. 8.1.1 Europe Leiomyosarcoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Leiomyosarcoma Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Leiomyosarcoma Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Leiomyosarcoma Drug Market Size by Country
  6. 8.2.1 Europe Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Leiomyosarcoma Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Leiomyosarcoma Drug Sales by Country
  2. 9.1.1 Asia-Pacific Leiomyosarcoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Leiomyosarcoma Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Leiomyosarcoma Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Leiomyosarcoma Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Leiomyosarcoma Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Leiomyosarcoma Drug Sales by Country
  2. 10.1.1 South America Leiomyosarcoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Leiomyosarcoma Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Leiomyosarcoma Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Leiomyosarcoma Drug Market Size by Country
  6. 10.2.1 South America Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Leiomyosarcoma Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Leiomyosarcoma Drug Sales by Country
  2. 11.1.1 Middle East and Africa Leiomyosarcoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Leiomyosarcoma Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Leiomyosarcoma Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Leiomyosarcoma Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Leiomyosarcoma Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Leiomyosarcoma Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Leiomyosarcoma Drug Value Chain Analysis
  2. 12.1.1 Leiomyosarcoma Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Leiomyosarcoma Drug Production Mode & Process
  7. 12.2 Leiomyosarcoma Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Leiomyosarcoma Drug Distributors
  10. 12.2.3 Leiomyosarcoma Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst